ESTIMATIVA DO AFILAMENTO DO FUSTE DE INDIVÍDUOS DE EUCALIPTO POR MEIO DE TÉCNICAS DE INTELIGÊNCIA ARTIFICAL

Objetivou-se com este trabalho definir configurações acuradas de redes neurais artificiais (RNA) para estimar o afilamento do fuste de indivíduos de eucalipto com seis anos de idade. Foi realizada uma cubagem rigorosa em um povoamento comercial no município de Paragominas, mesorregião sudeste do Estado do Pará. Para maior precisão de cubagem, todos os clones foram separados em três classes diamétricas, sendo abatidas cinco árvores por classe, totalizando 60 árvores abatidas. Para o banco de dados foram treinadas 240 RNA no software Neuro versão 4.06. As RNA treinadas foram do tipo Multilayer Perceptron (MLP), com o algoritmo de aprendizado Resilient Propagation RPROP+, com diferentes funções de ativação e arquitetura, sendo estas avaliadas quanto o bias, raiz quadrada do erro médio, variância, erro padrão da estimativa e coeficiente de correlação.  As RNA com menor valor ponderado foram as 165, 202, 204, 203 e 177, as quais apresentaram função de ativação do tipo sigmoidal. O coeficiente de correlação apresentou valores maiores que 0,99 para o treinamento e 0,98 para a validação das RNA, nas RNA treinadas. As RNA não foram tendenciosas e possuem capacidade de estimar o taper do eucalipto com acurácia. A RNA 165, com arquitetura de 5-7-1 e função de ativação sigmoidal, foi a que apresentou melhores resultados

ABORDAGEM MULTIDISCIPLINAR NO TRATAMENTO DE DOENÇAS CRÔNICA

Introdução: Sendo uma das principais causas de morte pelo mundo, as doenças crônicas se caracterizam por patologias com desenvolvimento gradual e de longa duração, podendo se estender por cerca de 6 meses ou se perdurar por toda a vida. Classificando-se em transmissíveis, causadas por um agente infeccioso e não transmissíveis frequentemente relacionadas à predisposição genética e estilo de vida. Objetivos: Revisar a abordagem multidisciplinar no tratamento de doenças crônicas. Metodologia: Pesquisa realizada entre abril e maio do ano de 2024, com base em uma revisão integrativa da literatura científica nas bases de dados SciELo e Biblioteca Virtual em Saúde (BVS), utilizando os descritores: "Doenças crônicas" e "Abordagem no tratamento para doenças crônicas". Resultados e discussão:  Resultados e discussão: A abordagem multidisciplinar no tratamento de doenças crônicas é fundamental para melhorar os resultados clínicos e a qualidade de vida dos pacientes. A participação de diferentes profissionais de saúde facilita a adesão ao tratamento e reduz maiores complicações. Conclusão: É essencial promover e implementar estratégias que incentivem a colaboração entre diferentes profissionais de saúde no manejo dessas condições, a fim de facilitar o processo do tratamento.&nbsp

EFEITOS DA PREMATURIDADE NO DESENVOLVIMENTO INFANTIL

Introduction: Prematurity, defined as birth before 37 completed weeks of gestation, is a condition that affects millions of babies around the world. Prematurity can result in a variety of medical complications and developmental delays that can have lasting, lifelong impacts and can occur for a variety of reasons, from complications during pregnancy to the mother's underlying medical conditions, genetic and environmental factors, becoming one of the main causes of neonatal morbidity and mortality in many countries, representing a significant challenge for health systems and affected families. Objectives: Objectively describe the impacts caused by prematurity on child development and the biggest challenges faced as a result of this factor. Methodology: Research carried out between April and May 2024, based on an integrative review of scientific literature in the SciELo and Virtual Health Library (VHL) databases, using the descriptors: “Prematurity” and “Child development”. Results and discussion: Prematurity has several impacts on child development, from delays in neurological evolution, physical growth to respiratory, immunological and nutritional health. Children born prematurely are at greater risk of developing cognitive and motor delays, attention deficits, hyperactivity and learning difficulties throughout their lives, facing challenges related to physical health and well-being. Conclusion: Premature babies face a series of challenges from the moment of birth, where they often require intensive care to ensure their survival and promote adequate growth and development. Furthermore, throughout childhood, these children often require specialized medical and therapeutic support to monitor and intervene in possible health complications, such as chronic respiratory, visual and hearing problems. Therefore, it is crucial to ensure a sensitive and welcoming care environment, in addition to offering emotional support to parents, to promote the best possible development for these children. Introdução: A prematuridade, definida como o nascimento antes das 37 semanas completas de gestação, é uma condição que afeta milhões de bebês em todo o mundo. A prematuridade pode resultar em uma variedade de complicações médicas e atrasos no desenvolvimento, que podem ter impactos duradouros ao longo da vida, podendo ocorrer por uma variedade de razões, desde complicações durante a gravidez até condições médicas subjacentes da mãe, fatores genéticos e ambientais, se tornando uma das principais causas de morbidade e mortalidade neonatais em muitos países, representando um desafio significativo para os sistemas de saúde e para as famílias afetadas. Objetivos: Descrever de forma objetiva quais os impactos causados pela prematuridade no desenvolvimento infantil e os maiores desafios enfrentados por consequência desse fator. Metodologia: Pesquisa realizada entre abril e maio do ano de 2024, com base em uma revisão integrativa da literatura científica nas bases de dados SciELo e Biblioteca Virtual em Saúde (BVS), utilizando os descritores: "Prematuridade", "Manejo da prematuridade" e "Desafios da prematuridade". Resultados e discussão: A prematuridade acarreta diversos impactos no desenvolvimento infantil, desde atrasos na evolução neurológica, no crescimento físico até a saúde respiratória, imunológica e nutricional. Crianças nascidas prematuramente apresentam maior risco de desenvolver atraso cognitivo e motor, déficits de atenção, hiperatividade e dificuldades de aprendizagem ao longo da vida, enfrentando desafios relacionados à saúde física e ao bem-estar. Conclusão: Os prematuros enfrentam uma série de desafios desde o momento do nascimento, onde muitas vezes necessitam de cuidados intensivos para garantir sua sobrevivência e promover um crescimento e desenvolvimento adequado. Além disso, ao longo da infância, essas crianças frequentemente necessitam de acompanhamento médico e terapêutico especializado para monitoração e intervenção em possíveis complicações de saúde, como problemas respiratórios crônicos, visuais e auditivos. Assim, é crucial garantir um ambiente de cuidados sensível e acolhedor, além de oferecer apoio emocional aos pais, para promover o melhor desenvolvimento possível para essas crianças.&nbsp

Paediatric COVID-19 mortality: a database analysis of the impact of health resource disparity

Background The impact of the COVID-19 pandemic on paediatric populations varied between high-income countries (HICs) versus low-income to middle-income countries (LMICs). We sought to investigate differences in paediatric clinical outcomes and identify factors contributing to disparity between countries.Methods The International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) COVID-19 database was queried to include children under 19 years of age admitted to hospital from January 2020 to April 2021 with suspected or confirmed COVID-19 diagnosis. Univariate and multivariable analysis of contributing factors for mortality were assessed by country group (HICs vs LMICs) as defined by the World Bank criteria.Results A total of 12 860 children (3819 from 21 HICs and 9041 from 15 LMICs) participated in this study. Of these, 8961 were laboratory-confirmed and 3899 suspected COVID-19 cases. About 52% of LMICs children were black, and more than 40% were infants and adolescent. Overall in-hospital mortality rate (95% CI) was 3.3% [=(3.0% to 3.6%), higher in LMICs than HICs (4.0% (3.6% to 4.4%) and 1.7% (1.3% to 2.1%), respectively). There were significant differences between country income groups in intervention profile, with higher use of antibiotics, antivirals, corticosteroids, prone positioning, high flow nasal cannula, non-invasive and invasive mechanical ventilation in HICs. Out of the 439 mechanically ventilated children, mortality occurred in 106 (24.1%) subjects, which was higher in LMICs than HICs (89 (43.6%) vs 17 (7.2%) respectively). Pre-existing infectious comorbidities (tuberculosis and HIV) and some complications (bacterial pneumonia, acute respiratory distress syndrome and myocarditis) were significantly higher in LMICs compared with HICs. On multivariable analysis, LMIC as country income group was associated with increased risk of mortality (adjusted HR 4.73 (3.16 to 7.10)).Conclusion Mortality and morbidities were higher in LMICs than HICs, and it may be attributable to differences in patient demographics, complications and access to supportive and treatment modalities

Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study

Background: Up to 30% of hospitalised patients with COVID-19 require advanced respiratory support, including high-flow nasal cannulas (HFNC), non-invasive mechanical ventilation (NIV), or invasive mechanical ventilation (IMV). We aimed to describe the clinical characteristics, outcomes and risk factors for failing non-invasive respiratory support in patients treated with severe COVID-19 during the first two years of the pandemic in high-income countries (HICs) and low middle-income countries (LMICs). Methods: This is a multinational, multicentre, prospective cohort study embedded in the ISARIC-WHO COVID-19 Clinical Characterisation Protocol. Patients with laboratory-confirmed SARS-CoV-2 infection who required hospital admission were recruited prospectively. Patients treated with HFNC, NIV, or IMV within the first 24 h of hospital admission were included in this study. Descriptive statistics, random forest, and logistic regression analyses were used to describe clinical characteristics and compare clinical outcomes among patients treated with the different types of advanced respiratory support. Results: A total of 66,565 patients were included in this study. Overall, 82.6% of patients were treated in HIC, and 40.6% were admitted to the hospital during the first pandemic wave. During the first 24 h after hospital admission, patients in HICs were more frequently treated with HFNC (48.0%), followed by NIV (38.6%) and IMV (13.4%). In contrast, patients admitted in lower- and middle-income countries (LMICs) were less frequently treated with HFNC (16.1%) and the majority received IMV (59.1%). The failure rate of non-invasive respiratory support (i.e. HFNC or NIV) was 15.5%, of which 71.2% were from HIC and 28.8% from LMIC. The variables most strongly associated with non-invasive ventilation failure, defined as progression to IMV, were high leukocyte counts at hospital admission (OR [95%CI]; 5.86 [4.83-7.10]), treatment in an LMIC (OR [95%CI]; 2.04 [1.97-2.11]), and tachypnoea at hospital admission (OR [95%CI]; 1.16 [1.14-1.18]). Patients who failed HFNC/NIV had a higher 28-day fatality ratio (OR [95%CI]; 1.27 [1.25-1.30]). Conclusions: In the present international cohort, the most frequently used advanced respiratory support was the HFNC. However, IMV was used more often in LMIC. Higher leucocyte count, tachypnoea, and treatment in LMIC were risk factors for HFNC/NIV failure. HFNC/NIV failure was related to worse clinical outcomes, such as 28-day mortality. Trial registration This is a prospective observational study; therefore, no health care interventions were applied to participants, and trial registration is not applicable

Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study

Background: Up to 30% of hospitalised patients with COVID-19 require advanced respiratory support, including high-flow nasal cannulas (HFNC), non-invasive mechanical ventilation (NIV), or invasive mechanical ventilation (IMV). We aimed to describe the clinical characteristics, outcomes and risk factors for failing non-invasive respiratory support in patients treated with severe COVID-19 during the first two years of the pandemic in high-income countries (HICs) and low middle-income countries (LMICs). Methods: This is a multinational, multicentre, prospective cohort study embedded in the ISARIC-WHO COVID-19 Clinical Characterisation Protocol. Patients with laboratory-confirmed SARS-CoV-2 infection who required hospital admission were recruited prospectively. Patients treated with HFNC, NIV, or IMV within the first 24 h of hospital admission were included in this study. Descriptive statistics, random forest, and logistic regression analyses were used to describe clinical characteristics and compare clinical outcomes among patients treated with the different types of advanced respiratory support. Results: A total of 66,565 patients were included in this study. Overall, 82.6% of patients were treated in HIC, and 40.6% were admitted to the hospital during the first pandemic wave. During the first 24 h after hospital admission, patients in HICs were more frequently treated with HFNC (48.0%), followed by NIV (38.6%) and IMV (13.4%). In contrast, patients admitted in lower- and middle-income countries (LMICs) were less frequently treated with HFNC (16.1%) and the majority received IMV (59.1%). The failure rate of non-invasive respiratory support (i.e. HFNC or NIV) was 15.5%, of which 71.2% were from HIC and 28.8% from LMIC. The variables most strongly associated with non-invasive ventilation failure, defined as progression to IMV, were high leukocyte counts at hospital admission (OR [95%CI]; 5.86 [4.83–7.10]), treatment in an LMIC (OR [95%CI]; 2.04 [1.97–2.11]), and tachypnoea at hospital admission (OR [95%CI]; 1.16 [1.14–1.18]). Patients who failed HFNC/NIV had a higher 28-day fatality ratio (OR [95%CI]; 1.27 [1.25–1.30]). Conclusions: In the present international cohort, the most frequently used advanced respiratory support was the HFNC. However, IMV was used more often in LMIC. Higher leucocyte count, tachypnoea, and treatment in LMIC were risk factors for HFNC/NIV failure. HFNC/NIV failure was related to worse clinical outcomes, such as 28-day mortality. Trial registration This is a prospective observational study; therefore, no health care interventions were applied to participants, and trial registration is not applicable

Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study

International audienceBackground: Up to 30% of hospitalised patients with COVID-19 require advanced respiratory support, including high-flow nasal cannulas (HFNC), non-invasive mechanical ventilation (NIV), or invasive mechanical ventilation (IMV). We aimed to describe the clinical characteristics, outcomes and risk factors for failing non-invasive respiratory support in patients treated with severe COVID-19 during the first two years of the pandemic in high-income countries (HICs) and low middle-income countries (LMICs).Methods: This is a multinational, multicentre, prospective cohort study embedded in the ISARIC-WHO COVID-19 Clinical Characterisation Protocol. Patients with laboratory-confirmed SARS-CoV-2 infection who required hospital admission were recruited prospectively. Patients treated with HFNC, NIV, or IMV within the first 24 h of hospital admission were included in this study. Descriptive statistics, random forest, and logistic regression analyses were used to describe clinical characteristics and compare clinical outcomes among patients treated with the different types of advanced respiratory support.Results: A total of 66,565 patients were included in this study. Overall, 82.6% of patients were treated in HIC, and 40.6% were admitted to the hospital during the first pandemic wave. During the first 24 h after hospital admission, patients in HICs were more frequently treated with HFNC (48.0%), followed by NIV (38.6%) and IMV (13.4%). In contrast, patients admitted in lower- and middle-income countries (LMICs) were less frequently treated with HFNC (16.1%) and the majority received IMV (59.1%). The failure rate of non-invasive respiratory support (i.e. HFNC or NIV) was 15.5%, of which 71.2% were from HIC and 28.8% from LMIC. The variables most strongly associated with non-invasive ventilation failure, defined as progression to IMV, were high leukocyte counts at hospital admission (OR [95%CI]; 5.86 [4.83-7.10]), treatment in an LMIC (OR [95%CI]; 2.04 [1.97-2.11]), and tachypnoea at hospital admission (OR [95%CI]; 1.16 [1.14-1.18]). Patients who failed HFNC/NIV had a higher 28-day fatality ratio (OR [95%CI]; 1.27 [1.25-1.30]).Conclusions: In the present international cohort, the most frequently used advanced respiratory support was the HFNC. However, IMV was used more often in LMIC. Higher leucocyte count, tachypnoea, and treatment in LMIC were risk factors for HFNC/NIV failure. HFNC/NIV failure was related to worse clinical outcomes, such as 28-day mortality. Trial registration This is a prospective observational study; therefore, no health care interventions were applied to participants, and trial registration is not applicable

Association of Country Income Level With the Characteristics and Outcomes of Critically Ill Patients Hospitalized With Acute Kidney Injury and COVID-19

Introduction: Acute kidney injury (AKI) has been identified as one of the most common and significant problems in hospitalized patients with COVID-19. However, studies examining the relationship between COVID-19 and AKI in low- and low-middle income countries (LLMIC) are lacking. Given that AKI is known to carry a higher mortality rate in these countries, it is important to understand differences in this population. Methods: This prospective, observational study examines the AKI incidence and characteristics of 32,210 patients with COVID-19 from 49 countries across all income levels who were admitted to an intensive care unit during their hospital stay. Results: Among patients with COVID-19 admitted to the intensive care unit, AKI incidence was highest in patients in LLMIC, followed by patients in upper-middle income countries (UMIC) and high-income countries (HIC) (53%, 38%, and 30%, respectively), whereas dialysis rates were lowest among patients with AKI from LLMIC and highest among those from HIC (27% vs. 45%). Patients with AKI in LLMIC had the largest proportion of community-acquired AKI (CA-AKI) and highest rate of in-hospital death (79% vs. 54% in HIC and 66% in UMIC). The association between AKI, being from LLMIC and in-hospital death persisted even after adjusting for disease severity. Conclusions: AKI is a particularly devastating complication of COVID-19 among patients from poorer nations where the gaps in accessibility and quality of healthcare delivery have a major impact on patient outcomes

Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry

Background: COVID-19 has been associated with a broad range of thromboembolic, ischemic, and hemorrhagic complications (coagulopathy complications). Most studies have focused on patients with severe disease from high-income countries (HICs). Objectives: The main aims were to compare the frequency of coagulopathy complications in developing countries (low- and middle-income countries [LMICs]) with those in HICs, delineate the frequency across a range of treatment levels, and determine associations with in-hospital mortality. Methods: Adult patients enrolled in an observational, multinational registry, the International Severe Acute Respiratory and Emerging Infections COVID-19 study, between January 1, 2020, and September 15, 2021, met inclusion criteria, including admission to a hospital for laboratory-confirmed, acute COVID-19 and data on complications and survival. The advanced-treatment cohort received care, such as admission to the intensive care unit, mechanical ventilation, or inotropes or vasopressors; the basic-treatment cohort did not receive any of these interventions. Results: The study population included 495,682 patients from 52 countries, with 63% from LMICs and 85% in the basic treatment cohort. The frequency of coagulopathy complications was higher in HICs (0.76%-3.4%) than in LMICs (0.09%-1.22%). Complications were more frequent in the advanced-treatment cohort than in the basic-treatment cohort. Coagulopathy complications were associated with increased in-hospital mortality (odds ratio, 1.58; 95% CI, 1.52-1.64). The increased mortality associated with these complications was higher in LMICs (58.5%) than in HICs (35.4%). After controlling for coagulopathy complications, treatment intensity, and multiple other factors, the mortality was higher among patients in LMICs than among patients in HICs (odds ratio, 1.45; 95% CI, 1.39-1.51). Conclusion: In a large, international registry of patients hospitalized for COVID-19, coagulopathy complications were more frequent in HICs than in LMICs (developing countries). Increased mortality associated with coagulopathy complications was of a greater magnitude among patients in LMICs. Additional research is needed regarding timely diagnosis of and intervention for coagulation derangements associated with COVID-19, particularly for limited-resource settings